ClinicalTrials.govpublic full text
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
prostatic neoplasms, castration-resistant, mcrpc, immune checkpoint inhibitors, immunotherapy, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 898078
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.